A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat
Authors:
Open Access
- 13 March 2017
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 34 (4) , 848-853
Abstract
This article informs the reader of the current information available on a novel therapeutic agent and new class of drug for the treatment of anemia. The data show promising results for alternative erythropoietin-stimulating agents and offers a time line of when Phase III data will be available. The information on this new drug and new drug class will change how nephrologists approach treating anemia within their patients.Keywords
This publication has 5 references indexed in Scilit:
- Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy StudyAmerican Journal of Kidney Diseases, 2016
- Roxadustat (FG-4592)Journal of the American Society of Nephrology, 2016
- Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patientsNephrology Dialysis Transplantation, 2015
- Prevalence of Anemia in Chronic Kidney Disease in the United StatesPLOS ONE, 2014
- Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trialNephrology Dialysis Transplantation, 2013